Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Anti-complement factor H (CFH) autoantibodies could be detected in lupus and its significance remained to be elucidated. Herein, we aimed to explore the roles of anti-CFH autoantibodies based on pristane-induced lupus mice.
Methods: Twenty-four female Balb/c mice were randomly divided into four groups, with one group injected with pristane (pristane group), one group with pristane and then human CFH (hCFH) (pristane-CFH group) 3 times, and the other two as vertical controls, PBS group and PBS-CFH group. Histopathological analysis was performed six months after pristane administration. Levels of hCFH, anti-CFH autoantibodies and anti-dsDNA antibody were detected. Murine IgG (mIgG) were purified and cross-reactivity, epitopes, subclasses and functional analysis were further evaluated in vitro.
Results: Immunization with hCFH and subsequent development of anti-CFH autoantibodies significantly attenuated nephritis of pristane-induced lupus, including lower levels of urinary protein and serum creatinine, decreased levels of serum anti-dsDNA antibody, greatly ameliorated renal histopathologic damage, decreased IgG, complements (C1q, C3) deposits and lower inflammatory factor (IL-6) expression in glomerulus. Furthermore, the purified mIgG (contained anti-CFH autoantibodies) could recognize both hCFH and murine CFH, and the epitopes were predominantly located in hCFH short consensus repeats (SCRs) 1-4, 7 and 11-14. The IgG subclasses were predominant IgG1. The autoantibodies could enhance the binding between hCFH and C3b, and increase factor I mediated-C3b lysis in vitro.
Conclusion: Our results suggested that anti-CFH autoantibodies could attenuate pristane-induced lupus nephritis by increasing bio-functions of CFH on regulating complement activation and controlling inflammation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667379 | PMC |
| http://dx.doi.org/10.1007/s12026-023-09396-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A tumor-binding antibody with cross-reactivity to viral antigens.
Cancer Immunol Immunother
February 2025
Department of Radiology, Duke University School of Medicine, Durham, NC, 27710, USA.
Background: We previously identified in non-small cell lung cancer (NSCLC) patients an autoantibody to complement factor H (CFH) that is associated with non-metastatic disease and longer time to progression in patients with stage I disease. A recombinant human antibody, GT103, was cloned from single B cells isolated from patients with the autoantibody. GT103 inhibits tumor growth and establishes an antitumor microenvironment.
View Article and Find Full Text PDFShiga toxin-producing Escherichia coli infection as a precipitating factor for atypical hemolytic-uremic syndrome.
Pediatr Nephrol
February 2025
UOC of Nephrology, Dialysis and Transplantation, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Article Synopsis
- Hemolytic uremic syndrome (HUS) is a serious condition that can happen after an infection or due to problems in the body's immune system, and there are two types: typical and atypical.
- This text discusses a 9-year-old boy who had a rare form of aHUS caused by specific genetic issues, which made his body produce autoantibodies that affected his kidneys and brain.
- The study found that many kids with aHUS needed kidney treatment and that early treatment with special therapy may help prevent kidney failure, even if the patient has infections like STEC.
An unusual case of adult-onset still's disease complicated with anti-complement factor H antibodies associated atypical haemolytic uraemic syndrome.
BMC Nephrol
May 2024
Division of Nephrology, Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong, China.
Background: Atypical haemolytic uremic syndrome (aHUS) is an uncommon form of thrombotic microangiopathy (TMA). However, it remains difficult to diagnose the disease early, given its non-specific and overlapping presentation to other conditions such as thrombotic thrombocytopenic purpura and typical HUS. It is also important to identify the underlying causes and to distinguish between primary (due to a genetic abnormality leading to a dysregulated alternative complement pathway) and secondary (often attributed by severe infection or inflammation) forms of the disease, as there is now effective treatment such as monoclonal antibodies against C5 for primary aHUS.
View Article and Find Full Text PDFAnti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange?
Pediatr Nephrol
November 2024
Pediatric Nephrology Department, Centre de référence des Maladies Rénales Rares MARHEA, Filières Maladies Rares ORKID et ERK-Net, Robert Debré Hospital, APHP, 48 bd Sérurier, 75019, Paris, France.
Article Synopsis
- A significant portion of atypical hemolytic uremic syndrome (aHUS) in children is linked to autoantibodies against complement factor H, prompting treatments like plasma exchange and eculizumab.
- In a study of 12 children treated with eculizumab, varying immunosuppressive strategies were used, but the decrease in anti-FH antibody levels was consistent regardless of the regimen.
- The study concluded that eculizumab is a safe and effective long-term treatment for aHUS related to anti-FH antibodies, and combining it with mycophenolate mofetil (MMF) may be sufficient for management.
Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody.
J Immunol
May 2024
Department of Integrative Immunobiology, Duke University School of Medicine, Durham, NC.
Article Synopsis
- Tumor-targeting antibodies can initiate an immune response vital for long-lasting cancer treatment.
- Researchers identified a specific antibody (GT103) that targets a unique form of the complement factor H (CFH) on tumor cells in lung cancer patients.
- In mouse models, a modified version of this antibody (mGT103) not only activates immune responses but also alters the tumor environment, making it more conducive to fighting cancer and enhancing the effectiveness of other treatments like anti-PD-L1 antibodies.